The meeting is scheduled for March 11, 2022
CHICAGO and TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, is pleased to announce that the U.S Food and Drug Administration (U.S. FDA) granted the Company’s request for a pre-IND (Investigational New Drug) meeting to discuss the novel therapy and proprietary protocol of SANA-013 for the treatment of Traumatic Brain Injury (TBI) related major depressive disorder (MDD).
In the pre-IND meeting, the Company expects to receive feedback from the FDA on its toxicology program and research to-date, in advance of IND clearance and initiation of the Phase I clinical trial, currently anticipated to occur in late 2022.
“This is a thrilling milestone in my nearly-decade long effort to find and advocate for treatments that provide hope to brain injury survivors,” said Daniel Carcillo, Wesana founder and CEO. “People who are suffering with severe TBI-related depression have a fivefold increase in suicide attempts and are 3 to 4 times more likely to die by suicide1 2. They deserve to have the best diagnostics and treatment options available to them, including a pharmaceutical option that doesn’t exasperate symptomology. We look forward to being able to move SANA-013 to a Phase I clinical trial as soon as possible.”
While there are a number of available therapies to treat depression, the success rate of antidepressants is only approximately 30 to 40%, highlighting the need for additional therapeutic options3. Further, despite the established importance of treating depression, only 44% of TBI patients with Major Depressive Disorder (MDD) received antidepressants or counseling4. Of those treated, there is limited evidence supporting the efficacy of antidepressants in the treatment of post-TBI depression5.
Wesana’s drug development program looks to utilize combination therapy to treat migraine and the symptoms associated with TBI, such as depression. By utilizing psilocybin and cannabidiol (“CBD”), a combination therapy of compounds with demonstrated effectiveness, SANA-013, is targeted to improve neuroplasticity and neurogenesis while acting as an anti-neuroinflammatory. In contrast to therapist assisted, single dose therapy, where a large dose of psilocybin is administered in clinic, which has exhibited poor durability and waning effects beginning as early as a few weeks post administration, SANA-013 utilizes a loading dose of psilocybin followed by self-administered maintenance doses of psilocybin and CBD to provide more sustained effects and benefit over time.
Mark A. Wingertzahn, Wesana’s Chief Scientific Officer said, “The data generated, and progress across Wesana’s drug development portfolio continues to exceed our expectations. This upcoming year is going to be important for Wesana as we continue to move through our development program with SANA-013 and have additional discussions on the development strategy and importance of this therapy with regulators in the U.S. and abroad.”
Please refer to the Company’s management’s discussion and analysis dated November 29, 2021, available on the Company’s profile on www.sedar.com for additional information as to the Company’s drug development program and the steps required to be completed for the Company to be able to commence phase I clinical trials.
About Wesana Health
Wesana Health helps people transcend barriers in mental health and performance. We innovate in care development through our therapies and proprietary protocols, and in care delivery through activating a new multidisciplinary, technology-supported clinical model. Learn more at www.wesanahealth.com.
1 Juengst SB, Kumar RG, Wagner AK. A narrative literature review of depression following traumatic brain injury: prevalence, impact, and management challenges. Psychol Res Behav Manag. 2017;10:175-186.
2 Oquendo MA, Friedman JH, Grunebaum MF, Burke A, Silver JM, Mann JJ. Suicidal behavior and mild traumatic brain injury in major depression. J Nerv Ment Dis. 2004;192(6):430-4.
3 Eaton WW, PI A, Kessler RC. The population dynamics of mental disorders Eaton WW, ed Public Mental Health. Oxford University Press, 2012:125-150.
4 Bombardier CH, Fann JR, Temkin NR, Esselman PC, Barber J, Dikmen SS. Rates of major depressive disorder and clinical outcomes following traumatic brain injury. JAMA. 2010;303(19):1938-45.
5 Robert S. Traumatic brain injury and mood disorders. Ment Health Clin. 2020;10(6):335-345.
CONTACT: For more information, please contact: Investor Contact: Keenan Gentry Email: IR@wesanahealth.com Phone: 773-236-7972 Media Contacts: Nick Opich / Fallon Carter KCSA Strategic Communications Email: Wesana@kcsa.com Phone: 212-896-1206 On behalf of the Board of Directors: Daniel Carcillo, Chief Executive Officer Phone: 773-236-7972
psilocybin wesana health wesana cse-aion otc-shrmf cse-plnt cse-betr cse-drug cse-tium cse-pwr cse-code cse-cool cse-tmed cse-delc cse-cbdt cse-enbi cse-ftrp cse-gblc cse-havn cse-holl cse-lobe cse-wuhn cse-mset cse-neon cse-spor cse-nova cse-nm cse-eat cse-opti cse-buzz cse-phrm otc-hstrf otc-vggf otc-betrf otc-bnoef asx-bno otc-bmbif otc-cntfm otc-cpivf otc-bkllf otc-clabf otc-cophf asx-cph neo-cybn otc-clxpf otc-evahf otc-ehvvf otc-delcf otc-epwcf otc-entbf otc-ftrpf otc-regrf nasdaq-gbnh tsxv-gtms otc-havlf otc-gtsif otc-mcurf neo-mcur neo-mmed otc-mmedf otc-msstf otc-mine otc-mycof otc-nmdbf otc-trmnf otc-nmlsf otc-nvmdf otc-lkysf cve-numi otc-splif otc-lmllf otc-phrrf cve-psyb otc-psycf cse-psyc cse-psyg otc-prxtf cse-pull otc-truff cse-trip otc-rwbyf cse-rwb otc-rvvtf cse-rvv otc-rmanf cve-litt nasdaq-seel otc-silo otc-shgff cse-shg otc-trssf cse-ter otc-pemtf cse-tbi otc-trypf cse-tyrp otc-xphyf cse-xphy nasdaq-cmps tsxv-cln otc-alid asx-ihl